A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis

Inclusion Criteria: * Subject whom should have the pathologically confirmed for unresectable (impossible to try Total mesorectal excision) rectal cancer with liver metastasis. * Over 18 years * ECOG 0-1 * Proper organ function (hepatic transaminases : \< ULN ⅹ5, Bilirubin: \< ULNⅹ2, creatinine (serum): \< ULNⅹ 1.5, PLT \> 100,000Ul, ANC \> 1,500/Ul * more than one target lesion (standard by RECIST 1.0) * Who should sign on the Informed consent form before participate the trial. Exclusion Criteria: * Metastasis in other organ except liver (No matter whether have resection or not) * Chronic active hepatitis or cirrhosis * History of treatment for colorectal cancer * Subject pregnant or breast feeding * Uncontrolled disease (eg. infection, hypertension, heart failure, Myocardial Infarction within 6months) * Have been used FOLFOX as an adjuvant therapy * Have had adjuvant therapy within 6months * Uncontrolled peripheral nerve infection * Alcoholic or drug addict * Subject currently is enrolled in or ≤30 days from ending other clinical trial. * History of other type of cancer except resolved from skin cancer and cervical cancer.